Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $20.00.
A number of analysts have recently issued reports on MNMD shares. Cantor Fitzgerald restated an “overweight” rating on shares of Mind Medicine (MindMed) in a research note on Friday, June 21st. Robert W. Baird initiated coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, May 28th. They issued an “outperform” rating and a $27.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $22.00 price target on shares of Mind Medicine (MindMed) in a report on Wednesday, June 5th. Baird R W raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a report on Wednesday, May 29th. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 24th.
Get Our Latest Stock Analysis on MNMD
Insider Buying and Selling at Mind Medicine (MindMed)
Hedge Funds Weigh In On Mind Medicine (MindMed)
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jump Financial LLC increased its position in shares of Mind Medicine (MindMed) by 8.3% during the 4th quarter. Jump Financial LLC now owns 36,826 shares of the company’s stock valued at $135,000 after purchasing an additional 2,826 shares during the last quarter. Citigroup Inc. purchased a new stake in shares of Mind Medicine (MindMed) during the 3rd quarter valued at about $273,000. Scotia Capital Inc. purchased a new stake in shares of Mind Medicine (MindMed) during the 4th quarter valued at about $441,000. Mitchell Mcleod Pugh & Williams Inc. purchased a new stake in shares of Mind Medicine (MindMed) during the 4th quarter valued at about $73,000. Finally, Bailard Inc. purchased a new stake in shares of Mind Medicine (MindMed) during the 4th quarter valued at about $63,000. Institutional investors own 27.91% of the company’s stock.
Mind Medicine (MindMed) Stock Up 2.8 %
Shares of MNMD stock opened at $7.27 on Monday. The company has a market capitalization of $510.86 million, a price-to-earnings ratio of -2.47 and a beta of 2.64. Mind Medicine has a 12-month low of $2.41 and a 12-month high of $12.22. The firm has a fifty day moving average of $8.36 and a 200-day moving average of $6.82. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 0.07.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.06. As a group, equities research analysts predict that Mind Medicine will post -1.36 earnings per share for the current fiscal year.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Stories
- Five stocks we like better than Mind Medicine (MindMed)
- There Are Different Types of Stock To Invest In
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- How Investors Can Find the Best Cheap Dividend Stocks
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Short Selling: How to Short a Stock
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.